VEGFA and endometrioid adenocarcinoma: Kamat et al. carried out a study in 111 patients with endometrioid adenocarcinoma about VEGF-A, an isomer of the VEGF family, finding that disease specific survival after treatment was significantly lower among high VEGF-A expressers compared with low VEGF-A expressers by means of univariate analysis and the relative risk of death.